Share on StockTwits

Stock analysts at Piper Jaffray started coverage on shares of Avalanche Biotechnologies (NASDAQ:AAVL) in a report issued on Monday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating and a $39.00 price target on the stock. Piper Jaffray’s price objective suggests a potential upside of 27.79% from the company’s current price.

Separately, analysts at Jefferies Group initiated coverage on shares of Avalanche Biotechnologies in a research note on Monday. They set a “buy” rating and a $40.00 price target on the stock.

Shares of Avalanche Biotechnologies (NASDAQ:AAVL) opened at 30.52 on Monday. Avalanche Biotechnologies has a one year low of $22.00 and a one year high of $32.375. The stock has a 50-day moving average of $26.28 and a 200-day moving average of $26.28. The company’s market cap is $651.9 million.

Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.

The Fly On The Wall

Receive News & Ratings for Avalanche Biotechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalanche Biotechnologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.